Boehringer Ingelheim and the Germans Trias i Pujol Research Institute strengthen their collaboration in preclinical research
The agreement between Boehringer Ingelheim and IGTP builds on a collaboration that began in 2020 to improve understanding of cardio-renal-metabolic diseases and their interconnection, and now includes the development of a new line of research to assess the potential of novel molecules in this field.